INSIGHTS ON CLINICAL TRIAL PARTNERING

• How To Select The Right Bioanalysis CRO For Your Program

  The right bioanalysis CRO accelerates progress, while the wrong one can derail outcomes. When every provider claims speed and credibility, how do you confidently choose the right partner?

• Tech Transfer Strategies For mAb Drug Products In Late-Phase Launch

  Tech transfer is not just a process of replicating manufacturing steps; it is a complex, multidisciplinary effort that ensures process robustness, scalability, regulatory compliance, and supply chain readiness.

• Why The TrialKit Platform License Agreement Changes The Economics Of Clinical Trials

  A platform‑based pricing model removes change‑order friction, enabling predictable budgets and faster study adjustments. It supports operational agility and portfolio‑level efficiency as trials evolve.

• Early-Stage Biotech's AI Advantage Is A Window That Closes

  The "greenfield" advantage allows biotechs to build AI-native trials from the start, replacing manual data entry with automated workflows and structured human oversight for better data integrity.

• New Purpose-Built Facility For Large-Scale Sterile Fill/Finish Operations

  7/17/2025

  Expanding capacity for late-phase clinical and large-scale commercial small molecule and biologic drugs, a new facility boosts sterile fill/finish capabilities.

• Empowering Mid-Size Pharma Companies With Integrated Drug Development, Regulatory Strategy, And AI Innovation

  10/23/2025

  A consultative, tech-enabled CRO can help mid-size pharma achieve targets by supplementing skillsets, expanding global reach, and designing an effective clinical, regulatory, and operational strategy.

• High Density, Low Availability: Rethinking Ophthalmic Trial Readiness

  4/16/2025

  The adoption of mobile ophthalmic solutions and collaboration with specialized vendors is recommended to ensure trial consistency and reach underserved regions.

• Building A Gold Standard Trial Experience In Japan

  4/4/2025

  Hear how Medable worked with a Japanese sponsor to elevate their trial experience, achieve >90% patient and site adherence, and beat their forecasted FPI date, creating new eCOA standards adopted across all the customer’s vendors.

• Flipping The Drug Development Industry On Its Head

  6/18/2024

  The video dives into the obstacles of the traditional outsourcing relationship between CROs and sponsors, and how Altasciences has broken from tradition to offer an alternative model.